Induction of concentration-dependent blockade in the G2 phase of the cell cycle by cancer chemotherapeutic agents.
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001761:Bleomycin / Q000494:pharmacology; D002453:Cell Cycle / Q000187:drug effects*; D002478:Cells, Cultured; D003513:Cycloheximide / Q000494:pharmacology; D003609:Dactinomycin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000494:pharmacology; D006918:Hydroxyurea / Q000494:pharmacology; D008154:Lucanthone / Q000494:pharmacology; D008937:Mitomycins / Q000494:pharmacology; D011691:Puromycin / Q000494:pharmacology
D000970:Antineoplastic Agents; D008937:Mitomycins; D001761:Bleomycin; D003609:Dactinomycin; D011691:Puromycin; D004317:Doxorubicin; D003513:Cycloheximide; D008154:Lucanthone; D006918:Hydroxyurea